C12N 2501/01
Modulators of camp or cgmp
Official title: Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
C12N2501/01 (Modulators of camp or cgmp) appears on 323 US grants and 587 published applications in this corpus.
Search patents in C12N- Granted patents
- 323
- Published applications
- 587
- Assignees
- 337
- Inventors
- 1,071
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 4 | 0 |
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 3 | 0 |
| 1998 | 9 | 0 |
| 1999 | 2 | 0 |
| 2000 | 7 | 0 |
| 2001 | 9 | 1 |
| 2002 | 3 | 14 |
| 2003 | 5 | 14 |
| 2004 | 7 | 19 |
| 2005 | 8 | 27 |
| 2006 | 5 | 19 |
| 2007 | 5 | 14 |
| 2008 | 5 | 17 |
| 2009 | 10 | 12 |
| 2010 | 9 | 15 |
| 2011 | 3 | 19 |
| 2012 | 10 | 21 |
| 2013 | 1 | 29 |
| 2014 | 12 | 22 |
| 2015 | 15 | 25 |
| 2016 | 16 | 29 |
| 2017 | 21 | 28 |
| 2018 | 26 | 30 |
| 2019 | 15 | 36 |
| 2020 | 20 | 30 |
| 2021 | 13 | 26 |
| 2022 | 12 | 33 |
| 2023 | 16 | 23 |
| 2024 | 19 | 45 |
| 2025 | 10 | 20 |
| 2026 | 13 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Complex microfluidic models for ALS including NF biomarkers for ALS research and drug development29 Sep 2026US 12,748,102 B2Cedars-Sinai Medical Center
- Method for obtaining endothelial cells from pluripotent stem cells1 Sep 2026US 12,723,237 B2Adhara
- Media for culturing naive human pluripotent stem cells14 Jul 2026US 12,680,083 B2Yeda Research and Development Co. Ltd.
- Stem cell-derived Schwann cells19 May 2026US 12,630,801 B2Memorial Sloan Kettering Cancer Center
- Oligonucleotides for inducing paternal UBE3A expression7 Apr 2026US 12,596,118 B2Hoffmann-La Roche Inc.
- Culture media and conditions for in vitro expansion and/or maturation of hepatocytes24 Sep 2026US 2026/0286311 A1Satellite Biosciences, Inc.
- Method for obtaining a neuromuscular organoid and use thereof3 Sep 2026US 2026/0258370 A1
- Generation of induced pluripotent stem cells with polycistronic sox2, klf4, and optionally c-myc6 Aug 2026US 2026/0226422 A1Beixcell (Beijing) Biotechnology Ltd.
- Method for producing metabolically activated liver organoid, composition, and method for evaluating test substance2 Jul 2026US 2026/0185054 A1Jsr Corporation
- Pde enhanced car-t cells25 Jun 2026US 2026/0174851 A1Koninklijke Philips N. V.
Most cited
By later US patents
- Adipose-derived stem cells and lattices313US 6,777,231 B1The Regents of the University of California · 2004
- Process for producing human antibodies246US 4,716,111 ATrustees of Boston University · 1987
- Adipogenic differentiation of human mesenchymal stem cells202US 5,827,740 AOsiris Therapeutics, Inc. · 1998
- Human embryonic pluripotent germ cells172US 6,090,622 AJohns Hopkins School of Medicine · 2000
- Adipogenic differentiation of human mesenchymal stem cells138US 6,322,784 B1Osiris Therapeutics, Inc. · 2001